5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 AFFIRM trial comparing enzalutamide to placebo
    Meeting Abstract

    Scher, H.; Fizazi, K.; Sternberg, C. N.; Armstrong, A.; Bhattacharya, S.; Hirmand, M.; de Bono, J.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Androgen receptor (AR) and AR-signaling directed therapies in the age of precision medicine
    Meeting Abstract

    Scher, H.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • HER2 tissue expression in NeuACT, a phase 2, randomised, open-label trial of DN24-02 in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence
    Meeting Abstract

    Press, M. F.; O'Donnell, P. H.; Plimack, E. R.; Hoffman-Censits, J.; Quinn, D. I.; Sharma, P.; DeVries, T.; Chen, M.; Locker, M.; Bajorin, D. F.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Long-term safety with sunitinib (SU) in metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Porta, C.; Gore, M. E.; Rini, B. I.; Escudier, B.; Charles, L. P.; Chen, L.; Hariharan, S.; Motzer, R. J.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • A validated prognostic model for predicting overall survival in patients with metastatic chemotherapy naive castrate-resistant prostate cancer
    Meeting Abstract

    Halabi, S.; Lin, C. Y.; Kelly, W. K.; Fizazi, K.; Moul, J. W.; Kaplan, E.; Morris, M. J.; Small, E. J.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Treatment sequencing following first-line sunitinib in patients (pts) with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Gore, M. E.; Hutson, T. E.; Lin, X.; Korytowsky, B.; Lechuga, M. J.; Matczak, E.; Figlin, R. A.; Bukowski, R.; Motzer, R. J.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • CA184-043: A randomized, multicenter, double-blind phase 3 trial comparing overall survival (OS) in patients (pts) with post-docetaxel castration-resistant prostate cancer (CRPC) and bone metastases treated with ipilimumab (ipi) vs placebo (pbo), each following single-dose radiotherapy (RT)
    Meeting Abstract

    Gerritsen, W. R.; Kwon, E. D.; Fizazi, K.; Bossi, A.; Van den Eertwegh, A.; Logothetis, C.; Scher, H. I.; Beer, T. M.; McHenry, M. B.; Gagnier, P.; more...
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Safety and efficacy of second-line axitinib versus sorafenib in metastatic renal cell carcinoma by duration of prior therapy: Subanalyses from a phase III trial
    Meeting Abstract

    Escudier, B.; Motzer, R. J.; Lim, H. Y.; Porfiri, E.; Zalewski, P.; Kannourakis, G.; Tarazi, J.; Rosbrook, B.; Kim, S.; Rini, B. I.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Assessing the impact of prior treatments on the efficacy of enzalutamide (ENZ): A subanalysis of the phase 3 AFFIRM trial
    Meeting Abstract

    de Bono, J.; Fizazi, K.; Shore, N.; Taplin, M.; De Wit, R.; Stenzl, A.; Hirmand, M.; Franks, B.; Scher, H.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Impact of prior antiandrogen exposure on clinical outcomes in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D)
    Meeting Abstract

    Bellmunt, J.; Yu, M. K.; Kheoh, T.; Taplin, M. E.; Davis, I. D.; Schnjvers, D.; Protheroe, A.; Molina, A.; de Bono, J. S.; Scher, H. I.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save